Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
Binnewies M, Pollack JL, Rudolph J, Dash S, Abushawish M, Lee T, Jahchan NS, Canaday P, Lu E, Norng M, Mankikar S, Liu VM, Du X, Chen A, Mehta R, Palmer R, Juric V, Liang L, Baker KP, Reyno L, Krummel MF, Streuli M, Sriram V.
Binnewies M, et al.
Cell Rep. 2021 Oct 19;37(3):109844. doi: 10.1016/j.celrep.2021.109844.
Cell Rep. 2021.
PMID: 34686340
Free article.
TREM2(+) TAMs are most enriched in individuals with ovarian cancer, where TREM2 expression corresponds to disease grade accompanied by worse recurrence-free survival. In an aggressive orthotopic ovarian cancer model, anti-TREM2 mAb therapy drives potent anti-tumor immunity …
TREM2(+) TAMs are most enriched in individuals with ovarian cancer, where TREM2 expression corresponds to disease grade accompanied by wo …